Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2).
Détails
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0
ID Serval
serval:BIB_EA3FA50DC390
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2).
Périodique
Open forum infectious diseases
Collaborateur⸱rice⸱s
Swiss HIV Cohort Study and the Swiss Transplant Cohort Study
Contributeur⸱rice⸱s
Abela I., Aebi-Popp K., Anagnostopoulos A., Battegay M., Bernasconi E., Braun D.L., Bucher H., Calmy A., Cavassini M., Ciuffi A., Dollenmaier G., Egger M., Elzi L., Fehr J., Fellay J., Furrer H., Fux C., Günthard H., Hachfeld A., Haerry D., Hasse B., Hirsch H., Hoffmann M., Hösli I., Huber M., Jackson-Perry D., Kahlert C., Kaiser L., Keiser O., Klimkait T., Kouyos R.D., Kovari H., Kusejko K., Labhardt N., Leuzinger K., de Tejada B.M., Marzolini C., Metzner K.J., Müller N., Nemeth J., Nicca D., Notter J., Paioni P., Pantaleo G., Perreau M., Rauch A., Salazar-Vizcaya L., Schmid P., Speck R., Stöckle M., Tarr P., Trkola A., Wandeler G., Weisser M., Yerly S., Amico P., Aubert J.D., Banz V., Beckmann S., Beldi G., Berger C., Berishvili E., Berzigotti A., Binet I., Bochud P.Y., Branca S., Bucher H., Catana E., Cairoli A., Chalandon Y., De Geest S., De Rougemont O., De Seigneux S., Dickenmann M., Dreifuss J.L., Duchosal M., Fehr T., Ferrari-Lacraz S., Garzoni C., Golshayan D., Goossens N., Haidar F., Halter J., Heim D., Hess C., Hillinger S., Hirsch H.H., Hirt P., Hoessly L., Hofbauer G., Huynh-Do U., Immer F., Koller M., Laesser B., Lamoth F., Lehmann R., Leichtle A., Manuel O., Marti H.P., Martinelli M., McLin V., Mellac K., Merçay A., Mettler K., Mueller N.J., Müller-Arndt U., Müllhaupt B., Nägeli M., Oldani G., Pascual M., Passweg J., Pazeller R., Posfay-Barbe K., Rick J., Rosselet A., Rossi S., Rothlin S., Ruschitzka F., Schachtner T., Schaub S., Scherrer A., Schnyder A., Schuurmans M., Schwab S., Sengstag T., Simonetta F., Stampf S., Steiger J., Stirnimann G., Stürzinger U., Van Delden C., Venetz J.P., Villard J., Vionnet J., Wick M., Wilhelm M., Yerly P.
ISSN
2328-8957 (Print)
ISSN-L
2328-8957
Statut éditorial
Publié
Date de publication
04/2023
Peer-reviewed
Oui
Volume
10
Numéro
4
Pages
ofad150
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Publication Status: epublish
Résumé
Extension of the COVERALL (COrona VaccinE tRiAL pLatform) randomized trial showed noninferiority in antibody response of the third dose of Moderna mRNA-1273 vaccine (95.3% [95% confidence interval {CI}, 91.9%-98.7%]) compared to Pfizer-BioNTech BNT162b2 vaccine (98.1% [95% CI, 95.9%-100.0%]) in individuals with different levels of immunosuppression (difference, -2.8% [95% CI, -6.8% to 1.3%]).
Mots-clé
HIV, Organ transplant, SARS-CoV-2, Vaccine, randomized trial
Pubmed
Web of science
Open Access
Oui
Création de la notice
26/01/2024 11:17
Dernière modification de la notice
01/03/2024 8:06
Données d'usage
